JNJ
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals
Johnson & Johnson
$231.29
+2.90 (+1.27%)
JNJ News30 articles
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Pfizer CFO Departure Casts Shadow on 2026 Growth Plans
Pfizer shares dropped 2.7% as CFO Dave Denton's departure raises fresh questions about the 2026 forecast and obesity drug pipeline.
Pfizer CFO Departure Raises Growth Strategy Questions, Stock Slips 3%
Pfizer shares slid 3.2% after announcing CFO Dave Denton's departure, intensifying investor scrutiny of the company's 2026 guidance and obesity drug strategy.
Amazon Ousts Walmart to Top Fortune 500, Reshaping Corporate Peeking Order
Amazon has claimed the top spot on the 2026 Fortune 500, ending Walmart's 13-year run and signaling a shift in corporate power driven by e-commerce, cloud computing, and healthcare.
Amazon Ousts Walmart as Fortune 500 Leader; Regional Giants Shine
Amazon unseats Walmart as Fortune 500 No. 1, breaking a 13-year streak. Erie Insurance rises, New Jersey boasts 15 firms, and New England has over 20 companies on the list.
Fairly Valued Defensive Stocks: J&J, Coca-Cola, P&G in Focus
Johnson & Johnson, Coca-Cola, and Procter & Gamble ended higher on Friday, but their valuations suggest they are fairly priced. Upcoming earnings calls will be crucial as the companies navigate litigation, tariffs, and input cost pressures.
J&J Stock Nears Record Highs on Promising Talvey Data
J&J shares rose 1.07% to $240.87 after new Talvey combination data showed up to 72% reduction in disease progression risk, bolstering the oncology pipeline.
SCHD's Heavy Top Holdings Raise Red Flags for Safety Seekers
SCHD's top 10 holdings now make up 43.5% of assets, raising concentration risk. With a 3.24% yield and $95.17B in assets, the fund's safety profile is under scrutiny.
J&J Shares Rise Amid Market Turmoil; Pipeline and Dividend in Focus
Johnson & Johnson shares rose 2.02% on Friday, outperforming the S&P 500, as a Los Angeles jury found the company not negligent in a talc lawsuit.
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.
Boston Scientific Plunges to Two-Year Low on Watchman Slowdown
Boston Scientific shares fell 10% to a two-year low after CEO Michael Mahoney flagged slower use of its Watchman heart implant, raising growth concerns.
JNJ Stock Rises on China Approval and Digital Surgery Deal
Johnson & Johnson shares gained 1.13% Friday to $234.34, climbing 3.4% for the week, buoyed by a Chinese approval of its drug nipocalimab and a new digital surgery partnership in Abu Dhabi.
AbbVie Stock Gains on Positive Pipeline Updates Ahead of Holiday
AbbVie closed Friday at $215.70, up 0.56%, after receiving a positive EU panel recommendation for MAVIRET in acute hepatitis C and releasing new oncology data ahead of ASCO.
Lloyds, SpaceX IPO, and Market Divergence Lead Today's Financial News
Lloyds Banking Group shares have risen 22% in the past year, showcasing strong dividend power. SpaceX files for a landmark IPO, while market divergence highlights tech optimism versus inflation concerns.
MeiraGTx Stock Dips 5.5% After Weekly Slide; FDA Designation and Funding in Focus
MeiraGTx shares fell 5.5% Friday to $9.40, ending a 4.3% weekly drop, as the company reported a Q1 net loss of $46.3 million and advanced regulatory filings for key gene therapies.
J&J Stock Dips on Friday but Posts Weekly Gain; Key Catalysts Ahead
J&J shares fell 1.77% Friday amid a broad selloff but still gained 2.4% for the week. Next week, investors watch pipeline data and a medtech launch.
Dow Dips 90 Points as AI Rally Lifts Nasdaq, S&P 500
The Dow slipped 90 points on Wednesday as AI and chip stocks drove the Nasdaq and S&P 500 higher. Hot producer prices and Kevin Warsh's Fed confirmation weighed on rate-cut expectations.
Intuitive Surgical Drops to 52-Week Low on Recall and Competition Fears
Intuitive Surgical shares fell to a 52-week low Monday after an FDA recall and lowered procedure growth forecasts, overshadowing a strong Q1 earnings beat.
Intuitive Surgical Hits 52-Week Low on FDA Class I Recall, Tariff Worries
Intuitive Surgical shares dropped 6.6% to a 52-week low after the FDA classified a recall of its SureForm stapler reloads as Class I, citing four injuries and one death. Strong Q1 earnings were overshadowed by tariff and safety concerns.
Wall Street Hits New Highs on Tech Surge; Dow Flat Despite Jobs Data
The S&P 500 and Nasdaq hit record highs Friday, driven by AI and semiconductor stocks, while the Dow Jones barely budged after a solid jobs report.
Dow Rises as Coca-Cola Gains Offset AI-Led Tech Selloff
The Dow Jones Industrial Average edged higher Tuesday as Coca-Cola's earnings boosted blue chips, while the Nasdaq slumped on AI sector concerns and rising oil prices.
Intuitive Surgical Shares Surge on Upgraded Forecast, Robust da Vinci Sales
Intuitive Surgical shares climbed to $482.22 after the company raised its 2026 growth outlook and reported a 23% revenue jump to $2.77 billion in Q1, driven by strong da Vinci system placements.
Tech Stocks Drive Market Gains Amid Ceasefire Relief and Earnings Strength
U.S. stocks climbed Wednesday, with the Nasdaq leading gains as technology shares rallied following an extended Iran ceasefire and a wave of corporate earnings. Oil prices remained elevated near $100 a barrel.
Lilly's $7B Kelonia Buy Targets In Vivo CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal worth up to $7 billion, gaining an in vivo CAR-T therapy currently in Phase 1 trials for multiple myeloma.
Lilly Acquires Kelonia in $7B Bet on In-Body CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal valued at up to $7 billion, gaining an experimental in-body CAR-T therapy for blood cancer. Lilly shares rose 2.5% on the news.
Definium's Psychedelic Drug DT120 Gains Analyst Backing Ahead of Key 2026 Data
Definium Therapeutics advanced after Stifel and Piper Sandler issued Buy ratings, spotlighting its LSD-based drug DT120 in late-stage trials for anxiety and depression. The company will host an investor day on April 22 to discuss upcoming Phase 3 data expected through 2026.
Stocks Climb as Oil Retreats, Inflation Data Eases Rate Fears
U.S. equities advanced Tuesday, with the Dow Jones Industrial Average rising approximately 290 points, bolstered by a sharp decline in oil prices and wholesale inflation data that was cooler than anticipated.
Wall Street Rallies on Diplomatic Hopes, Strong Bank Earnings
U.S. stocks advanced sharply Tuesday, with major indexes climbing as hopes for renewed U.S.-Iran talks and a solid start to earnings season lifted market spirits. The Dow gained over 290 points.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.